

Sidharth G. Sharma, M.D.  
[sidharthgsharma@gmail.com](mailto:sidharthgsharma@gmail.com)  
(702) 625-3799

December 8, 2020

To: The Annual Review NV Medicaid P&T Review Neurological Agents:

I am writing to the Nevada P&T Committee to please consider adding Ubrelvy (ubrogepant) onto the Preferred Drug List formulary for the treatment of acute migraine with or without aura in adults.

This medication has served favorable outcomes to my patients. This medication has provided my patients with an excellent non-narcotic option for rapid relief of pain related to migraines, which has proven to be a boon during the current opioid epidemic. Furthermore, this medication has an excellent cardiovascular profile as well. I have prescribed Ubrelvy to several patients over the course of this past year with excellent feedback. Thank you for your consideration, and I hope my comments assist you in making a determination for your review.

I am licensed by the State of Nevada to practice medicine. My license number is 16901 and was issued on January 24, 2017.

Sincerely,



Sidharth G. Sharma, M.D.  
Diplomate of the American Board of Psychiatry and Neurology  
Fellow of the American Psychiatric Association